Durham, NC – According to filings with the U.S. Securities and Exchange Commission, IMMvention Therapeutix is raising $4,402,504.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Anil Goyal played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About IMMvention Therapeutix

Stealth-mode venture-funded company. Discovering and developing first-in-class novel small molecule pan-inflammasome inhibitors for treating inflammatory diseases. “First-in-class”, pan-inflammasome small molecule inhibitors for more effective control of inflammation beyond just NLRP3.

To learn more about IMMvention Therapeutix, visit http://immventionthera.com/

Contact:
Anil Goyal, Chief Executive Officer
919-593-6230
https://www.linkedin.com/in/goyalanilk/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved